We reported recently a marked reduction in IKB kinase A (IKKA) expression in a large proportion of human poorly differentiated squamous cell carcinomas (SCC) and the occurrence of Ikka mutations in human SCCs. In addition, overexpression of IKKA in the epidermis inhibited the development of skin carcinomas and metastases in mice. However, whether a reduction in IKKA expression promotes skin tumor development is currently unknown. Here, we assessed the susceptibility of Ikka hemizygotes to chemical carcinogen-induced skin carcinogenesis. Ikka +/À mice developed 2 times more papillomas and 11 times more carcinomas than did Ikka +/+ mice. The tumors were larger in Ikka +/À than in Ikka +/+ mice, but tumor latency was shorter in Ikka +/À than in Ikka +/+ mice. Some of the Ikka +/À papillomas and most Ikka +/À carcinomas lost the remaining Ikka wild-type allele. Somatic Ikka mutations were detected in carcinomas and papillomas. The chemical carcinogen-induced H-Ras mutations were detected in all the tumors. The phorbol ester tumor promoter induced higher mitogenic and angiogenic activities in Ikka +/À than in Ikka +/+ skin. These elevated activities were intrinsic to keratinocytes, suggesting that a reduction in IKKA expression provided a selective growth advantage, which cooperated with H-Ras mutations to promote papilloma formation. Furthermore, excessive extracellular signal-regulated kinase and IKK kinase activities were observed in carcinomas compared with those in papillomas. Thus, the combined mitogenic, angiogenic, and IKK activities might contribute to malignant conversion. Our findings provide evidence that a reduction in IKKA expression promotes the development of papillomas and carcinomas and that the integrity of the Ikka gene is required for suppressing skin carcinogenesis. [Cancer Res 2007;67(19):9158-68] 
Introduction
We recently reported somatic IjB kinase a (Ikka) mutations in human squamous cell carcinomas (SCC) and a marked reduction in IKKa expression in poorly differentiated human and mouse cutaneous SCCs (1) , which highlights the importance of IKKa in human skin cancer. However, the natural role for IKKa in skin tumor development is unclear. The animal model provides an appropriate tool to address these questions.
IKKa is one subunit of the IKK complex, which is central for nuclear factor-nB (NF-nB) activation (2) . Its involvement in the development of lymphoid organs and innate immunity requires IKK/NF-nB activity (3, 4) . IKKa also plays an essential role in the formation of the epidermis during embryonic development in mice (5) (6) (7) . Ikka À/À mice develop a striking hyperplastic epidermis that lacks terminal differentiation and these mice die at birth (5) (6) (7) . Ikka À/À keratinocytes and skin preserve IKK/NF-nB activity (5, 8) .
Reintroduction of IKKa or kinase-inactive IKKa induced terminal differentiation in Ikka À/À keratinocytes, but reintroduction of IKKh, RelA p65, or InBa (an inhibitor for NF-nB) failed to do so (8) . Furthermore, Sil et al. (9) reported that IKKa or kinase-inactive IKKa transgene driven by the keratin 14 promoter rescued the skin phenotype of Ikka À/À mice. These results suggest that the function of IKKa in determining the epidermal formation is IKK/NF-nB independent.
We reported recently that Lori.IKKa transgenic mice developed normal skin and that the elevated IKKa in the suprabasal epidermis enhanced terminal differentiation markers (1) . These transgenic mice developed significantly fewer malignant carcinomas and metastases than did wild-type (WT) mice when they were challenged with the chemical carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) and tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). The mitogenic and angiogenic activities were reduced in the DMBA/TPA-treated skin of Lori.IKKa mice relative to those in the DMBA/TPA-treated skin of WT mice. These results suggest that elevated IKKa expression antagonizes chemical carcinogen-induced mitogenesis and angiogenesis, thereby repressing the development of malignant carcinomas and metastases. However, the effect of reduced IKKa on skin tumor development is unknown.
Ras plays a prominent role in the development of human SCCs and H-Ras mutations are frequently found in human SCCs (10, 11) . Ras activation is required for chemical carcinogen-induced skin carcinogenesis in mice. The carcinogen DMBA causes activating H-Ras mutations, and the tumor promoter TPA expands the population of Ras-initiated cells (12, 13) . Most papillomas eventually regress, and only a few become carcinomas in mice with a C57BL6 or a C56BL/129/Sv background (14, 15) . Mice lacking H-Ras developed significantly fewer skin tumors than did WT mice induced by DMBA/TPA (16) . In the present study, we tested the susceptibility of Ikka hemizygotes to DMBA/TPA-induced skin carcinogenesis. Ikka +/À mice developed 2 times more benign tumors (papillomas) and 11 times more malignant carcinomas than did WT mice. Furthermore, we found that most Ikka +/À carcinomas and some Ikka +/À papillomas lost the remaining WT Ikka allele. These findings show that reduction in IKKa expression promotes papilloma formation and malignant conversion.
Materials and Methods
Mice and skin carcinogenesis. All the mice used in this study were cared for in accordance with the guidelines of our institution's Animal Care and Use Committee (animal protocol 04-01-05732). DMBA (Sigma-Aldrich, Inc.) and TPA (LC Laboratories) were used to treat mice. Six-to 8-week-old female Ikka +/+ and Ikka +/À mice with a C57BL6 background (C57BL6/129/ Sv mice were backcrossed with C57BL6 mice thrice) were topically treated with 100 Ag DMBA in 200 AL acetone; 2 weeks later, the mice were treated with 2.5 Ag TPA in 200 AL acetone five times weekly for 28 weeks. For controls, 15 Ikka +/+ and 15 Ikka +/À mice were treated with 100 Ag DMBA in acetone (no TPA) and 15 Ikka +/+ and 15 Ikka +/À mice were treated with 2.5 Ag TPA in acetone (no DMBA) five times weekly for 28 weeks. For bromodeoxyuridine (BrdUrd; Sigma-Aldrich) incorporation experiment, mice were treated with 2.5 Ag TPA in 200 AL acetone or 200 AL acetone alone as a control five times weekly for 4 weeks or with 100 Ag DMBA in 200 AL acetone once. BrdUrd (0.05 mg/g body weight) was administered i.p. to mice 1 h before they were killed. Skin specimens were embedded in paraffin and then sectioned, and BrdUrd labeling was counted in 1,000 cells in the basal epidermis. Immunohistochemical BrdUrd detection was done in our Histology and Tissue Core.
1 Paraffin-embedded sections of tumor tissue and skin were prepared, and routine H&E and immunohistochemical staining of these sections with antibodies against proliferating cell nuclear antigen (PCNA) and IKKa were done in our Histology and Tissue Core.
Detection of H-Ras (V61 and V12) mutations. Analyses for H-Ras mutations were done in our Molecular Biology Core.
2 PCR primers for HRas codon 61 mutation detection were 5 ¶-ggtgtaggctggttctgtggattctc-3 ¶ and 5 ¶-gcacacggaaccttcctcac-3 ¶, which generated a 329-bp band that was gel purified and used for a second PCR round. PCR primers for the second round were 5 ¶-tgtggattctctggtctgaggagag-3 ¶ and 5 ¶-cataggtggctcacctgtactgatg-3 ¶, which produced a 269-bp fragment. The PCR products were digested with XhaI. PCR primers for H-Ras codon 12 mutation detection were 5 ¶-cctggattggcagccgctgt-3 ¶ and 5 ¶-tcatactcgtccacaaagtg-3 ¶, which generated a 125-bp fragment. The fragments were digested with MnII.
Real-time PCR. Total RNA was isolated from skin, tumors, and keratinocytes by TRI reagent (Molecular Research Center, Inc.), and cDNA was synthesized by a RETROscript kit (Ambion, Inc.). The PCR primers and probes were purchased from Applied Biosystems [tumor necrosis factor a (TNFa), Mm00443258_m1; interleukin-1a (IL-1a), Mm00439620_m1; transforming growth factor a (TGFa), Mm00446231_m1; vascular endothelial growth factor-A (VEGF-A), Mm00437304_m1; epidermal growth factor (EGF), Mm00438696_m1; amphiregulin, Mm00437583_m1; heparin-binding EGF (HB-EGF), Mm00439307_m1; fibroblast growth factor 2 (FGF2), Mm00433287_m1; and FGF13, Mm00438910_m1]. The reactions were done according to the manufacturer's instructions. Each cDNA sample was analyzed in triplicate by an ABI 7900 sequence detector (Applied Biosystems). Thermal cycling was done as follows: 1 cycle at 50jC for 2 min and 95jC for 10 min and 40 cycles at 95jC for 15 s and 60jC for 1 min. Data were analyzed by the Prism Dissociation Curve software program (SDS 2. 2. 2, Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control.
Southern blot analysis. DNA was isolated from tumors and normal skin by an extraction kit (Promega). DNA (10 Ag) was digested with BamHI overnight, applied to a 0.9% agarose gel, transferred to blotting membranes (Zeta-Probe GT, Bio-Rad), and fixed by UV light. The DNA blotting membranes were hybridized with an NH 2 -terminal IKKa cDNA (nucleotides 1-575) probe and a 400-bp NH 2 -terminal GAPDH cDNA probe as a control. Southern blotting was done according to the manufacturer's instructions (Bio-Rad).
Western blotting. A cell lysate (40 Ag) was applied to SDS gel, and specific protein levels were measured by Western blotting as described previously (8) with the following antibodies against IKKa (Imgenex), phosphorylated extracellular signal-regulated kinase (p-ERK; Cell Signaling Technology), ERK1 (Santa Cruz Biotechnology), ERK2 (Santa Cruz Biotechnology), and h-actin (Sigma).
Keratinocyte culture. Mouse primary keratinocytes were isolated and cultured as described previously (8) . Briefly, skin specimens isolated from newborn mice or E19 embryos were treated with 0.25% trypsin (Life Technologies) for 8 to 10 h at 4jC; the epidermis was separated from the dermis. Isolated keratinocytes were plated on 60-cm cell dishes containing keratinocyte serum-free medium (Life Technologies).
Ikka mutation analysis. Total RNA was isolated from skin or tumors with TRI reagent, and cDNA from these samples was synthesized by a RETROscript kit. The PCR fragments were generated by an expanded highfidelity plus PCR system (Roche Diagnostics GmbH) with primers (IKKa, 5 ¶-ccattcactattctgaggttggtgtc-3 ¶ and 5 ¶-tactggaggggttactgtgccttc-3 ¶). The PCR products were subcloned into pGEM-T vectors (Promega) and sequenced (1) . The sequences were compared with the National Center for Biotechnology Information, gi 6680941.
Chromatin immunoprecipitation assay. Chromatin immunoprecipitation (ChIP) assay was done following the manufacturer's instructions (Upstate). Keratinocytes were starved for 24 h (no growth factors) and cells were treated with EGF (10 ng/mL) for 24 h or with TPA (48 nmol/L) for 2 h. After cells were fixed, washed, and collected, their DNA was sheared by sonication in 200 AL lysis buffer. Then, 20 AL sonicated DNA from each sample was purified and used as an input DNA control. The rest of the DNA was precleared. The chromatin DNA was precipitated with an anti-IKKa antibody and protein A/G beads, and the DNA was eluted from the beads. The precipitated DNA was analyzed by PCR for 1 cycle at 95jC for 5 min; 35 cycles at 95jC for 20 s, 55jC for 20 s, and 72jC for 30 s; and 1 cycle at 72jC for 10 min. The PCR primers for proximal VEGF-A promoters (À903 to À1,233 bp) were 5 ¶-gtgttcctgagcccagtttgaag-3 ¶ and 5 ¶-agtccgctgaatagtctgccttg-3 ¶ and the primers for distal VEGF-A promoter (À2,414 to À2,065 bp) were 5 ¶-tgggttagaggtgggggttttg-3 ¶ and 5 ¶-aactgaagccagggtgccaatg-3 ¶. PCR primers for analyzing the mRNA level of VEGF-A (491 bp) were 5 ¶-gcacccacgacagaaggagagcaga-3 ¶ and 5 ¶-cgccttggcttgtcacatctgcaa-3 ¶.
Results

Ikka
+/À mice develop many more and larger skin tumors earlier than do Ikka +/+ mice. To determine the relationship between IKKa expression and skin carcinogenesis, we topically treated Ikka +/+ and Ikka +/À mice with a single dose of DMBA followed by repeated treatment with TPA. At week 28 of TPA treatment, we collected and weighed the tumors. Ikka +/À mice developed significantly more tumors than did Ikka +/+ mice (P < 0.0005, linear regression model; Table S1B) . To determine the rate of carcinoma conversion, we histologically examined all the tumors that weighed >0.03 g. Four of the 125 (3.2%) tumors that developed in the 15 Ikka +/+ mice and 47 of the 285 (16.5%) tumors that developed in the 15 Ikka +/À mice were carcinomas (P < 0.005, Fisher's exact test; Fig. 1C ). These results suggested that Ikka +/À mice were far more susceptible to skin carcinogenesis than Ikka +/+ mice. Genetic background affects the susceptibility of mice to chemical carcinogen-induced skin carcinogenesis (15) . Although the mice used for this study were not 100% C57BL6, Ikka +/À and Ikka +/+ mice were sisters. Mice with a mixed C57BL6 genetic background have been used for the studies of chemical carcinogen-induced skin carcinogenesis (14, 17) . In addition, the differences in the tumor incidence and the tumor multiplicity between Ikka +/+ group and Ikka +/À group were dramatically significant. Thus, it was likely that the genetic background was not a major factor that caused these differences. We also examined apoptotic cells in tumors from Ikka +/+ and Ikka +/À mice by immunostaining analysis and did not observe a significant difference for this end point between Ikka +/+ and Ikka +/À tumors (data not shown). H-Ras mutations are detected in papillomas and carcinomas. The papillomas in the Ikka +/+ and Ikka +/À mice displayed welldifferentiated patterns with a thick surface layer of keratin. The carcinomas were less differentiated or undifferentiated in the Ikka +/+ and Ikka +/À mice ( Fig. 2A) . The carcinomas expressed PCNA in the entire tumor, but the papillomas expressed PCNA only in the hyperproliferating basal cells ( Fig. 2A) .
To determine whether these skin tumors were initiated by DMBA-mediated H-Ras mutations, we examined V61 mutations (CAA!CTA) of H-Ras in randomly selected papillomas and carcinomas from Ikka +/+ and Ikka +/À mice by using PCR. The H-Ras (V61) mutations were detected in 19 of 23 (82.6%) Ikka +/+ tumors and in 24 of 28 (85.7%) Ikka +/À tumors (Fig. 2B) . Moreover, we found V12 mutations (GGA!GGC) in the tumors that were negative for V61 mutations of H-Ras (Fig. 2C) . We did not detect any H-Ras mutations in seven untreated skin specimens of Ikka +/+ and Ikka +/À mice, respectively, and in eight DMBA/TPA-treated skin specimens of Ikka +/+ and Ikka +/À mice, respectively. These results suggested that all the skin tumors were initiated by DMBAmediated H-Ras mutations. Levels of IKKA proteins are markedly reduced in most Ikka +/À carcinomas and some Ikka +/À papillomas. We further evaluated the IKKa level in papillomas and carcinomas. Western blotting analysis showed higher levels of IKKa in 10 papillomas than in skin specimens from Ikka +/+ mice (Fig. 3A) . The increased IKKa could be induced by long-term treatment with TPA, as suggested by Saleem et al. (18) . We reported previously that poorly differentiated SCCs expressed markedly reduced IKKa (1). Reduction in IKKa was also detected in the 8 poorly differentiated carcinomas of the 15 Ikka +/+ carcinomas ( Fig. 3A ; Supplementary S2A and B). Furthermore, some of the 17 Ikka +/À papillomas expressed elevated IKKa, but the remainder expressed reduced IKKa (Fig. 3A) . All 18 Ikka +/À carcinomas expressed markedly reduced IKKa. Comparison of IKKa relative levels suggested that the IKKa levels were inversely correlated with the increased numbers of carcinomas (Fig. 3B) . Immunohistochemical staining showed a reduction in IKKa expression only in carcinomas, not in the skin that surrounded the tumors (Fig. 3C) . Collectively, these results suggested that a reduction in IKKa expression contributed to the formation of papillomas; a further reduction greatly enhanced the development of carcinomas, although the mechanism by which IKKa was reduced might be different in Ikka +/+ and Ikka +/À tumors. Genetic alterations of Ikka occur in skin tumors. We reported previously that the poorly differentiated carcinomas expressed reduced IKKa proteins; however, IKKa mRNA levels were not reduced in these carcinomas obtained from WT mice (1), and we observed similar results in this study ( Supplementary  Fig. S2B ). In addition, we observed that papillomas and carcinomas from Ikka +/À mice tended to lose IKKa (Fig. 3A) probe covering exons 1 to 6 of Ikka (Fig. 4A ). This probe hybridized with three fragments, including a 9.3-kb fragment from exon 2 to upstream of the Ikka gene, a 3.6-kb fragment from exons 3 to 4, and a 5.2-kb fragment from exons 5 to 9 in Ikka +/+ cells (Fig. 4B) . In the Ikka À/À cells, the 5.2-kb fragment disappeared because exon 7 in the Ikka allele included a neo gene that contained two additional BamHI sites at its 5 ¶ and 3 ¶ ends ( Fig. 4A  and B Fig. S3A ; ref.
5). Reverse transcription-PCR (RT-PCR) confirmed that Ikka
+/À carcinomas retained low levels of IKKa mRNA ( Supplementary  Fig. S3B ). Collectively, these results indicated that LOH of Ikka might be largely responsible for loss of IKKa protein in Ikka +/À carcinomas and papillomas.
We then examined the Ikka gene in 11 papillomas and 7 carcinomas from Ikka +/+ mice by Southern blotting with the IKKa cDNA probe and found no alterations in Ikka ( Fig. 4C ; . D, detection of Ikka mutations including mutations, deletions, and insertions in 45 clones from four Ikka +/+ carcinomas. *, mutations; #, insertion; }, deletion. Thirty-three clones from two acetone-treated skin specimens were used as background controls.
Supplementary Table S3 ). Ikka mutations in human SCCs were reported previously (1). To identify mutations in the Ikka murine gene, we used RT-PCR to amplify an IKKa transcript (nucleotides 1606-2090; amino acids 518-679 of IKKa; NM_007700) from either acetone-treated control skins or Ikka +/+ carcinomas. Amplified PCR products were subcloned into the pGEM vectors and sequenced. We sequenced 33 clones from two acetone-treated skin samples, which were used as PCR background controls (5 and 6 in Supplementary Table S4 Table S2 ). Thus, Ikka mutations might also contribute to loss of IKKa proteins in carcinomas if some cells in carcinomas retained the remaining WT Ikka allele. Apparently, there were more Ikka mutations in carcinomas than in papillomas. These transition and transversion nucleotide substitutions caused missense and nonsense mutations (Fig. 4D) . Although we detected some repeated mutations in the same tumors, the frequency of the repeated mutations was low, suggesting that these somatic mutations were not amplified, which was consistent with our previous results (1) . In addition, sequencing results confirmed that the mutations were not homologous ( Supplementary Fig. S3C ). Collectively, Ikka mutations were found in both human and mouse SCCs.
Reduction in IKKA expression enhances mitogenic activity in skin and carcinomas. A previous study suggested that ERK activity was a signature for Ras-initiated skin tumors in two-stage chemical carcinogenesis settings (17) . We found H-Ras mutations in the tested papillomas and carcinomas. Because control mice treated with DMBA alone did not produce any tumors at 28 weeks, we investigated the effect of reduced IKKa on the promotion of TPA-induced tumors. Immunohistochemical staining showed a higher fraction of BrdUrd-positive cells in the epidermis of Ikka +/À mice than in the epidermis of Ikka +/+ mice treated with TPA (P = 0.009, Student's t test; Fig. 5A ), suggesting that TPA enhanced cell proliferation in Ikka +/À skin. We next examined phosphorylation of ERK, a downstream target of Ras. ERK activity was higher in Ikka +/À than in Ikka +/+ cultured keratinocytes under routine culture conditions (Supplementary Fig. S4 ). ERK activity was much higher in TPA-treated Ikka +/À than in TPA-treated Ikka +/+ skin (Fig. 5B) . Furthermore, examination of several growth factors that are downstream targets of TPA (12) by real-time PCR showed excessive expression of TGFa, EGF, amphiregulin, FGF2, FGF13, VEGF-A, and TNFa in TPA-treated Ikka +/À skin specimens relative to that in TPA-treated Ikka +/+ skin specimens (Fig. 5C ). TPA moderately elevated expression of HB-EGF and IL-1 in Ikka +/À compared with that in Ikka +/+ skin. The basal levels of ERK activity and expression of these growth factors were slightly higher in Ikka +/À than in Ikka +/+ skin ( Fig. 5B and C) . Moreover, we isolated keratinocytes from Ikka +/+ and Ikka +/À newborn mice and found that TPA treatment induced significant higher levels of ERK activities and higher expression levels of the growth factors in Ikka +/À keratinocytes than in Ikka +/+ keratinocytes ( Fig. 5D and E) , suggesting that the increased mitogenic activity was intrinsic to keratinocytes. Western blotting showed considerably higher ERK activity in carcinomas than in papillomas (Fig. 5F ). Collectively, these results indicated that reduced IKKa markedly elevated TPAinduced ERK activity and expression of these growth factors, which provided a molecular basis for promoting keratinocyte proliferation, papilloma formation, and malignant conversion in Ikka
Because IKKa is one subunit of the IKK complex, we then evaluated IKK activity. Kinase assay showed that IKK activity was only slightly increased in TPA-treated Ikka +/À compared with that in TPA-treated Ikka +/+ skin specimens; the levels of IKKh were similar in these skin specimens (Supplementary Fig. S5) . However, the IKK activity was higher in carcinomas than in papillomas, although the IKKh level was not increased in carcinomas (Fig. 5G) . The levels of InBa were found to be lower in some carcinomas than in papillomas (Supplementary Fig. S6A ). To determine whether IKKa loss deregulated expression of IKKh and InBa, we examined their levels in the epidermis. Western blotting showed that Ikka
and Ikka À/À epidermis expressed similar levels of IKKh, InBa, and p65 ( Supplementary Fig. S6B ). Presumably, the replacement of IKKa by IKKh in the IKK complex might contribute to the increased IKK kinase activity in IKKa-deficient cells as suggested by three previous reports (8, (19) (20) (21) .
Loss of IKKA promotes VEGF-A expression and blood vessel formation. Our skin carcinogenesis experiments showed that Ikka +/À mice developed 11 times more carcinomas than did Ikka +/+ mice (Fig. 1C) . VEGF-A, an important angiogenesis factor, promotes neovascularization and the onset of tumor invasion (22) . We reported previously that overexpression of IKKa repressed Ras-induced VEGF-A expression; binding of IKKa to a distal VEGF-A promoter (À2,414 to À2,065 bp) was correlated to a decrease in VEGF-A expression (1) . In the present study, we observed elevated VEGF-A expression in Ikka +/À compared with that in Ikka +/+ skin specimens and keratinocytes ( Fig. 5C and E) . It has been reported that EGF enhances VEGF-A expression (23) . We thus examined whether reduced IKKa elevated VEGF-A expression and blood vessel formation. ChIP assay showed that EGF treatment reduced binding of IKKa to the distal VEGF-A promoter, which was associated with elevated EGF-A expression in Ikka +/+ keratinocytes ( Fig. 6A-C) . Reintroduced IKKa bound to the distal VEGF-A promoter and repressed VEGF-A expression in Ikka À/À keratinocytes ( Fig. 6A-C) . IKKa did not bind to the proximal VEGF-A promoter (Fig. 6A) , which was consistent with our previous finding (1). Furthermore, we found that TPA and DMBA dramatically enhanced the formation of blood vessels in the skin of Ikka +/À mice relative to that in the skin of Ikka +/+ mice (Fig. 6D) . Significantly . B, levels of p-ERK and ERK1/2 in skin specimens treated with TPA for 4 wks, detected by Western blotting. b-Actin , loading control. C, relative levels of indicated growth factor and cytokine mRNA in the skin specimens, detected by real-time PCR. D, ERK activities in Ikka +/À (+/À) and Ikka +/+ (+/+) primary cultured keratinocytes, which were starved overnight before TPA treatment, detected by Western blotting. b-Actin, protein loading control. E, relative levels of indicated growth factor mRNA in primary cultured keratinocytes as detected by real-time PCR. Control (C ); TPA treatment for 2 h (T ). F, levels of p-ERK and ERK in Ikka +/+ and Ikka +/À skin specimens, papillomas, and carcinomas, detected by Western blotting (WB ). G, IKK kinase activity and IKKh levels in papillomas, carcinomas, and skin specimens, detected by immunocomplex kinase assay (KA) with an anti-IKKg antibody. IKKg recovery was determined by Western blotting. GST-IjBa (1-54 amino acids ), IKK kinase substrate; IP, immunoprecipitation; Su-KA, kinase substrate; +/+, Ikka +/+ ; +/À, Ikka
more blood microvessels in the skin stroma of Ikka +/À mice than in the skin stroma of Ikka +/+ mice were also observed after treatment with DMBA/TPA for 14 weeks ( Supplementary Fig. S7A and B) . Thus, IKKa loss-enhanced VEGF-A expression might foster the development of carcinomas in Ikka +/À mice.
Discussion
In the present study, we found that Ikka +/À mice developed many more and larger tumors than did Ikka +/+ mice; the latency period for tumor appearance was shorter in Ikka +/À mice than in Ikka +/+ mice (Fig. 1A-D) , indicating that a reduction in IKKa expression provided a selective growth advantage, which promoted the formation of skin tumors. Elevated ERK activity has been suggested as a signature event for Ras-initiated skin tumors (17) . For example, ERK activity and H-Ras mutations were not detected in skin carcinomas that lost the remaining WT Pten allele in Pten +/À mice (17) . H-Ras mutations were detected in all the tumors in our mice and elevated ERK activity was observed in carcinomas compared with those in papillomas, which suggested that reduced IKKa provided a selective growth advantage that cooperated with DMBA-induced H-Ras mutations to promote skin carcinogenesis. Our results further showed that TPA treatment induced excessive ERK activity and excessive expression of EGF, TGFa, amphiregulin, FGF2, FGF13, and VEGF-A in Ikka +/À skin specimens. The elevated mitogenic activity was intrinsic to keratinocytes, which was consistent with a previous study, in which the expression levels of a group of FGFs and ERK activity were dramatically higher in Ikka À/À skin and keratinocytes than in Ikka +/+ skin and keratinocytes and that reintroduction of IKKa or kinase-inactive IKKa repressed ERK activity and expression of FGFs (9) . The mitogenic activity was associated with the nuclear function of IKKa (9) . Thus, a reduction in IKKa expression induced excessive mitogenic activities following TPA treatment, which provided a molecular basis for promoting keratinocyte proliferation and papilloma formation. Elevated ERK activity and excessive expression of growth factors were reported previously to contribute to the malignant conversion during skin carcinogenesis (17, 24) . In addition, IKKa loss enhanced expression of VEGF-A that was likely to be important for tumor invasion ( Fig. 6A-D We showed previously that elevated IKKa expression repressed chemical carcinogen-induced mitogenic and angiogenic activities in the epidermis and the dermis of Lori.IKKa transgenic mice (1). The IKKa transgenic mice developed significantly fewer malignant carcinomas and metastases than did WT mice. Here, we report that reduced IKKa expression promoted chemical carcinogen-or growth factor-induced mitogenic and angiogenic activities and that Ikka +/À mice were far more prone to skin carcinogenesis than were Ikka +/+ mice. These findings suggest that IKKa-associated mitogenic and angiogenic activities are important mechanism in repressing or promoting skin carcinogenesis.
Moreover, we observed elevated IKK kinase activity in carcinomas compared with that in papillomas, although the levels of IKKh were not elevated in the carcinomas. In addition, the levels of InBa were reduced in some carcinomas ( Fig. 5G ; Supplementary S6A). Loss of IKKa was not found to elevate the levels of IKKh or down-regulate the levels of InBa in the epidermis (Supplementary Fig. S6B ). Previous findings suggested that IKKh replacement for IKKa in the IKK complex elevated the IKK kinase activity in IKKa-deficient cells because IKKh showed a stronger kinase activity for InBs than did IKKa (8, (19) (20) (21) . Thus, IKKa loss or other indirect causes might be involved in the IKK kinase activation in the carcinomas. Increased IKK kinase activity has been implied to promote tumor progression through a variety of avenues (26) . Increased IKKh-dependent IKK activity was reported to promote human cancer development and colitis-associated cancer in mice (27, 28) . Reduced InBa levels and increased NF-nB activities were observed previously in chemical carcinogeninduced carcinomas compared with those in papillomas (29) . In addition, IKKa loss was reported to promote the expression of cytokines, such as TNFa (19) , and we also detected elevated expression of TNFa in IKKa-deficient keratinocytes (data not shown). Thus, elevated IKK/NF-nB activity might promote skin carcinogenesis in Ikka +/À mice, although the detailed mechanisms remain to be elucidated.
We previously reported somatic Ikka mutations in human SCCs (1) . In this study, we also observed Ikka mutations in carcinomas and papillomas, suggesting that the Ikka gene might be a susceptible target for mutagenesis during skin carcinogenesis. Recently, Greenman et al. (30) reported that Ikka (Chuk) mutations were frequently detected in human cancers after examining mutations in 518 genes. We found more transition mutations (T!C and A!G) than transversion mutations (Supplementary Tables S4 and S5) , which was consistent with our previous report (1) . Some of the mutations resulted in changed amino acids, which might destabilize IKKa or alter IKKa activity. Some of the mutations created the stop codon, which presumably generated a truncated IKKa protein. We also detected deletions and insertions in the IKKa transcripts, which caused frameshift mutations for IKKa. Seemingly, there were more Ikka mutations in carcinomas than in papillomas, suggesting that the increased numbers of Ikka mutations might contribute to destabilization of IKKa in skin carcinomas. Furthermore, we found some repeated mutations in different tumors, which might be ''hotspots.'' We also noticed more Ikka mutations in DMBA/TPA-induced mouse SCCs than those in human SCCs (1), which might be due to repeated treatments with a high dose of TPA for inducing skin tumors in mice. It is known that TPA can increase the amount of intracellular oxidative damage that influences the potential for DNA damage in cells (31) . However, we previously observed markedly reduced IKKa expression in poorly differentiated human SCCs (1). Possibly, in addition to Ikka mutations, IKKa in human SCCs can be down-regulated by alternative pathways. For example, p63 was reported to regulate IKKa expression in the formation of the epidermis, and deregulated p63 expression was involved in skin tumor development (32) (33) (34) . Oncogenic stress, mutations, or unbalanced alleles can cause LOH of genes in tumors (14, 35, 36) . We observed that 44% of the Ikka +/À papillomas and 95% of the Ikka +/À carcinomas lost the remaining WT Ikka allele. Ikka +/À mice developed 11 times more carcinomas than did Ikka +/+ mice. These results suggested that the integrity of the Ikka gene was important for suppressing malignant conversion. The development of malignancies is complex; more mechanisms remain to be revealed.
